| Literature DB >> 30300620 |
Aaron Stewart1, Ian Yates2, Deanna Mudie3, Perrine Pivette4, Aaron Goodwin1, Alyssa Sarmiento2, Marcus Winter2, Michael Morgen1, David Vodak1.
Abstract
Spray-dried dispersions (SDDs) are an important technology for enhancing the oral bioavailability of poorly water-soluble drugs. To design an effective oral SDD formulation, the key rate-determining step(s) for oral drug absorption must be understood. This work combined in vivo and in vitro tests with in silico modeling to identify the rate-determining steps for oral absorption of belinostat SDDs made with 3 different polymers (PVP K30, PVP VA64, and HPMCAS-M). The goal was developing a belinostat SDD formulation that maximizes oral bioavailability (ideally matching the performance of a belinostat oral solution) and defining critical performance attributes for formulation optimization. The in vivo pharmacokinetic study with beagle dogs demonstrated that 1 of the 3 SDDs (PVP K30 SDD) matched the performance of the oral solution. In vitro data coupled with in silico modeling elucidated differences among the SDDs and supported the hypothesis that absorption of belinostat in the small intestine from the other 2 SDDs (PVP VA64 and HPMCAS-M) may be limited by dissolution rate or reduced drug activity (maximum concentration) in the presence of polymer. It was concluded that drug concentration in the stomach before emptying into the proximal intestine is a key factor for maximizing in vivo performance.Entities:
Keywords: absorption; amorphous solid dispersion; belinostat; bioavailability; dissolution; pharmacokinetic modeling; pharmacokinetics; polymer; spray drying; spray-dried dispersion
Mesh:
Substances:
Year: 2018 PMID: 30300620 DOI: 10.1016/j.xphs.2018.09.031
Source DB: PubMed Journal: J Pharm Sci ISSN: 0022-3549 Impact factor: 3.534